Keçeli Sema Aşkın
Kocaeli University Faculty of Medicine, Department of Medical Microbiology, Kocaeli, Turkey.
Mikrobiyol Bul. 2017 Oct;51(4):404-412. doi: 10.5578/mb.54128.
Opportunistic fungal infections like invasive candidiasis and aspergillozis have high mortality rate particularly in immunosupressive patients. The rate of therapy success with antifungal agents is usually low. Although immunotherapy methods have been developed to increase the host response against antifungals, there has been a need for new antifungal therapeutic agents in the treatment of invasive aspergillozis and other opportunistic fungal infections. Mycoviruses are the viruses that specifically infect fungi. The use of mycoviruses in the treatment of invasive fungal infections has not been suggested yet. However, as mentioned in this review, the researches about the use of mycoviruses as a therapeutic agent have been still carried on. Mycoviruses have no infectivity as free particules. Many of them have RNA genome. They are classified as: Fungi containing "double stranded (ds) RNA, ds DNA or single stranded RNA". Although most of them are found in plant pathogenic fungi, they are also found in human pathogenic fungi. In most of the mycoviruses identified up to now, dsRNA genome are present. Mycoviruses that can be pathogenic for human and carrying dsRNA genome have been classified as Partitiviridae, Totiviridae, Chrysoviridae, Reoviridae and Hypoviridae. A part of mycoviruses may not cause any sign of infection in fungal host. The other part of mycoviruses causes hypovirulence or lethal effect. When hypovirulence occured in fungi, the observed effects are the decrease in pigmentation, mycelium formation, asexual sporulation, growing rate and the loss of fertility. The transfer of mycovirus to fungi may occur by intracellular or extracellular way. The transfer of genetic content to fungi occurs in two way: transformation and transfection. In both ways, there is a need for a spheroblast that has no cell wall. There are various scenarios about mycoviruses for the their use in the treatment. In the first scenario, the transfer of selective mycovirus is ensured by extracellular way, and then the binding of mycovirus to target fungus by genetic modifications is aimed. The second scenario is about the use of mycovirus as a vector for genetic transformation. In fact, this method is applied by using toxins in fungal diseases of plants. In addition, the production of lethal antibodies or peptides derived from antibodies obtained from toxin-coding cytoplasmic dsRNA mycovirus toxins may be a new therapeutic approach. It has been claimed that these derivatives may be used as parentheral therapeutic agents against human pathogenic fungi including Candida albicans. In this review article, the importance of mycoviruses in mycology has been discussed.
侵袭性念珠菌病和曲霉病等机会性真菌感染的死亡率很高,尤其是在免疫抑制患者中。抗真菌药物的治疗成功率通常较低。尽管已经开发出免疫疗法来增强宿主对抗真菌药物的反应,但在侵袭性曲霉病和其他机会性真菌感染的治疗中,仍需要新的抗真菌治疗药物。真菌病毒是专门感染真菌的病毒。目前尚未有人提出使用真菌病毒来治疗侵袭性真菌感染。然而,正如本综述中所提到的,关于将真菌病毒用作治疗剂的研究仍在进行中。真菌病毒作为游离颗粒没有感染性。它们中的许多具有RNA基因组。它们被分类为:含有“双链(ds)RNA、ds DNA或单链RNA”的真菌。尽管它们中的大多数存在于植物致病真菌中,但也存在于人类致病真菌中。在迄今为止鉴定出的大多数真菌病毒中,存在dsRNA基因组。可对人类致病且携带dsRNA基因组的真菌病毒已被分类为双分病毒科、全病毒科、金黄病毒科、呼肠孤病毒科和低毒病毒科。一部分真菌病毒可能不会在真菌宿主中引起任何感染迹象。另一部分真菌病毒会导致低毒力或致死效应。当真菌出现低毒力时,观察到的影响是色素沉着减少、菌丝体形成、无性孢子形成、生长速度下降和生育能力丧失。真菌病毒向真菌的转移可能通过细胞内或细胞外方式发生。遗传物质向真菌的转移有两种方式:转化和转染。在这两种方式中,都需要一个没有细胞壁的球状体。关于真菌病毒在治疗中的应用有各种设想。在第一种设想中,通过细胞外方式确保选择性真菌病毒的转移,然后旨在通过基因改造使真菌病毒与目标真菌结合。第二种设想是关于将真菌病毒用作基因转化的载体。事实上,这种方法是在植物真菌病害中通过使用毒素来应用的。此外,从编码毒素的细胞质dsRNA真菌病毒毒素获得的致死抗体或抗体衍生肽的生产可能是一种新的治疗方法。有人声称,这些衍生物可作为针对包括白色念珠菌在内的人类致病真菌的肠胃外治疗剂。在这篇综述文章中,讨论了真菌病毒在真菌学中的重要性。